Intelligence Profile
Research Papers
Research Papers and Clinical Trials
The available research on alpha-lipoic acid (ALA) covers several therapeutic areas, though evidence specifically for intravenous administration is limited in the provided studies.
Diabetic Neuropathy Research
The most robust evidence comes from diabetic neuropathy studies. The OPTIMUM Study was a randomized, open-label, non-inferiority Phase IV clinical trial examining the combination of pregabalin and alpha-lipoic acid in patients with painful diabetic peripheral neuropathy, published in Diabetes, Obesity & Metabolism in 2026. However, the specific sample size and detailed results are not provided in the available information.
A separate study published in Nutrients (2024) evaluated a multi-ingredient formulation containing alpha-lipoic acid alongside palmitoylethanolamide, superoxide dismutase, B vitamins, vitamin E, magnesium, zinc, and nicotinamide over 6 months in people with diabetic neuropathy. The study design and sample size are not specified in the available data.
Cancer-Related Applications
Research has explored ALA's potential in cancer treatment contexts. A study published in Experimental Oncology (2025) investigated the prevention of paclitaxel-induced motor neuropathy using alpha-lipoic acid and ipidacrin hydrochloride in breast cancer patients, though specific methodology details are not available.
Conversely, a preclinical study published in Clinical Medicine Insights: Oncology (2024) found that combining high-dose parenteral ascorbate (vitamin C) with alpha-lipoic acid failed to enhance tumor-inhibitory effects and actually increased toxicity in preclinical cancer models.
Clinical Trial Activity
Several completed clinical trials have investigated compounds related to alpha-lipoic acid, particularly CPI-613 (a lipoic acid analog) in various cancer types including metastatic pancreatic cancer and small cell lung cancer. These were Phase I studies, though detailed results are not provided.
One completed trial (NCT05360602) specifically examined alpha-lipoic acid's effect on no-reflow phenomenon, though the phase and results are not specified.
Evidence Limitations
The available evidence provides limited detail on study methodologies, sample sizes, and specific outcomes. Most studies appear to focus on oral or combined formulations rather than intravenous alpha-lipoic acid specifically. The research spans multiple therapeutic areas but lacks comprehensive data on IV administration protocols, dosing, or comparative effectiveness.
This information is for educational purposes only and should not replace professional medical advice. Consult healthcare providers for treatment decisions.